Browse communities
Browse communities
Presenting a webinar?

Retention Mechanisms in HILIC Chromatography: Robust Method Development

David S. Bell, Ph.D.
Hydrophilic interaction liquid chromatography (HILIC), especially in conjunction with mass spectrometry (MS), has become a powerful tool for the analysis of a wide variety of challenging analytes. Applications of the technique have increased dramatically over the past decade, especially for the analysis of polar analytes where reversed-phase chromatography suffers. HILIC conditions employ a high percentage of acetonitrile which enables facilitated solvent evaporation in LC/MS sources and thus often an increase in analyte response when compared to more aqueous based systems. The increased retention of polar analytes afforded by HILIC provides improved selectivity and decreases the impact of endogenous species, often leading to improved qualitative and quantitative analyses.

Although HILIC has proven useful, it has also been thwarted with complications including difficulties in method development and method robustness.

In this presentation, studies investigating the underlying retention mechanisms dominant in HILIC chromatography are presented and discussed. Along with reversed-partitioning HILIC is well known to exhibit, ion-exchange and the interplay of the dominant mechanisms are unveiled and used to develop a model of overall retention and selectivity. Interactions that operate using different stationary phase chemistries and conditions are presented. The impact of analyte polarity and charge as well as the variations caused by high percentages of organic on these physiochemical parameters are highlighted. Throughout the discussion, examples of use and misuse of HILIC are employed to illustrate these important concepts to build a solid fundamental foundation for efficient and effective use of this powerful technique.
Jun 28 2012
55 mins
Retention Mechanisms in HILIC Chromatography:  Robust Method Development
More from this community:

Medical Research

  • Live and recorded (465)
  • Upcoming (20)
  • Date
  • Rating
  • Views
  • C-H functionalization is a powerful addition to the toolbox of the medicinal chemist. Modern C-H functionalization techniques hold the potential to enable the rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the preparation of biological probes. This presentation will describe a variety of high-value C-H functionalization chemistries, developed in house and in collaboration with academic groups, and give examples of how these technologies have been deployed successfully to impact drug discovery programs.
  • How can ischemia impact your assay results? Watch this video and see...
  • This webinar will discuss the evolving role of Cell Lines and Cell Culture and their usefulness as models of physiological function and disease. The webinar will review the depth, breadth and best use of currently available Cell Lines. The role played by Cell Lines in ensuring that the output of future research continues to be valid and credible will also be evaluated. This is the first of a three part webinar series focused on delivering a broad picture of the role of cell lines as models in scientific research, the various strategies and approaches available.
  • Abstract:
    There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.

    This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.

    Speaker Biography:
    Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
  • Mass spectrometry and other methods such as yeast two-hybrid can now accurately discern protein complexes or larger protein interactomes in diseases such as cancer, yet it is difficult to forward translate this knowledge into human samples. To overcome this hurdle, we began experiments using proximity ligation assays (PLA) to directly translate protein complexes into human tumor materials. Our assay reflects protein complexes between EGFR and GRB2 protein, a key adaptor protein necessary for EGFR pathway activation and coupling to downstream MAPK signaling. We annotated nearly 300 primary xenograft models (PDX) of cancer and show tumor subtype enrichment of EGFR:GRB2 signaling-associated complexes. Furthermore, tumors with abundant levels of EGFR:GRB2 signaling-associated complexes are more likely to respond to anti-EGFR antibody-based therapy. Finally, in 350 lung cancer tissues, across three distinct cohorts of patients, we demonstrate the ability of EGFR:GRB2 protein complexes to segregate tumors and show benefit to EGFR tyrosine kinase inhibitor therapy in patients whose tumors harbor high levels of EGFR:GRB2 signaling-associated complexes. This suggests that annotation of signaling-associated protein complexes in cancer tissues can not only molecularly annotate disease types but may also have predictive capacity for cancer therapeutics. This work opens up the human protein interactome as a new class of molecular markers for disease in a more practical manner. Proteins, encoded by DNA, do not work in isolation but instead function as part of multi-protein complexes that drive both normal and disease physiology. While we demonstrate the utility of this approach in cancer, receptor tyrosine kinase signaling and tyrosine kinase inhibitor therapeutics, our approach described here could have utility across a wide spectrum of both signaling-associated complexes and different types of disease, and thus would be attractive to a large audience.
  • This webinar will discuss the evolving role of Cell Lines and Cell Culture and their usefulness as models of physiological function and disease. The webinar will review the depth, breadth and best use of currently available Cell Lines. The role played by Cell Lines in ensuring that the output of future research continues to be valid and credible will also be evaluated. This is the first of a three part webinar series focused on delivering a broad picture of the role of cell lines as models in scientific research, the various strategies and approaches available.
  • Mass spectrometry and other methods such as yeast two-hybrid can now accurately discern protein complexes or larger protein interactomes in diseases such as cancer, yet it is difficult to forward translate this knowledge into human samples. To overcome this hurdle, we began experiments using proximity ligation assays (PLA) to directly translate protein complexes into human tumor materials. Our assay reflects protein complexes between EGFR and GRB2 protein, a key adaptor protein necessary for EGFR pathway activation and coupling to downstream MAPK signaling. We annotated nearly 300 primary xenograft models (PDX) of cancer and show tumor subtype enrichment of EGFR:GRB2 signaling-associated complexes. Furthermore, tumors with abundant levels of EGFR:GRB2 signaling-associated complexes are more likely to respond to anti-EGFR antibody-based therapy. Finally, in 350 lung cancer tissues, across three distinct cohorts of patients, we demonstrate the ability of EGFR:GRB2 protein complexes to segregate tumors and show benefit to EGFR tyrosine kinase inhibitor therapy in patients whose tumors harbor high levels of EGFR:GRB2 signaling-associated complexes. This suggests that annotation of signaling-associated protein complexes in cancer tissues can not only molecularly annotate disease types but may also have predictive capacity for cancer therapeutics. This work opens up the human protein interactome as a new class of molecular markers for disease in a more practical manner. Proteins, encoded by DNA, do not work in isolation but instead function as part of multi-protein complexes that drive both normal and disease physiology. While we demonstrate the utility of this approach in cancer, receptor tyrosine kinase signaling and tyrosine kinase inhibitor therapeutics, our approach described here could have utility across a wide spectrum of both signaling-associated complexes and different types of disease, and thus would be attractive to a large audience.
  • Today use of the term “single use technologies” can be considered as being synonymous with the modern biotech industries. Based on the proliferation of companies now specialising in providing solutions to pretty much anyone anywhere, along with the intensive level of marketing and industry discussion, it is clear to see that the sector has progressed significantly over the years. The ability to purchase systems and technologies off the shelf as a consumable, rather than invest in significant capital infrastructure, better facilitates small enterprises to perform small and pilot GMP scale manufacture in-house. Organisations are able to leverage the experience of the manufacturers in the development of these products. The concept of single use technologies has been proven to produce solutions which are compliant and work. However, there still are questions around regulatory guidance for single use technologies.
  • Channel
  • Channel profile
  • Interplay of Acetyltransferase EP300 and the Proteasome System in Regulat-Sess.2 May 21 2015 8:00 pm UTC 75 mins
    Mirko Theis & Christian Loew
    In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • Interplay of Acetyltransferase EP300 and the Proteasome System in Regu-Session 1 May 21 2015 12:00 pm UTC 75 mins
    Mirko Theis & Christian Loew
    In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • Duolink in Biomedical Science, Session 2 Apr 28 2015 3:00 pm UTC 75 mins
    J. Matthew Rhett, PhD Instructor, Department of Surgery, Medical University of South Carolina
    Gap junctions (GJs) are large aggregates of intercellular channels that facilitate the diffusion of small molecules and ions between two interacting cells. GJ intercellular channels are formed through the interaction of two half-channels, called hemichannels, composed of oligomerized connexin protein subunits. Both GJs and hemichannels have numerous important physiological and pathological roles in tissue functions including propagation of the action potential in the heart, tumor growth and metastasis, the inflammatory response and adaptive immunity, wound healing, and electrical synaptic transmission in the central nervous system. The most widely expressed connexin isoform is Cx43, and its regulation in the abovementioned processes has been a major focus of GJ research. Over the past two decades protein-protein interaction with the cytoplasmic carboxyl terminus of Cx43 has come to the fore as an endogenous mechanism for controlling the GJ life cycle, channel gating, and channel-independent functions. We have used the Duolink proximity ligation assay (PLA) as a technique to study protein interactions with Cx43 in cultured cells. Two unique aspects of the technology – specifically, subcellular localization and the binary nature of the labeling – in combination with standard immunofluorescent confocal imaging techniques have yielded unexpected insights into GJ ultrastructure, action potential conduction, and the mechanistic regulation of Cx43 trafficking and hemichannel accretion to GJ plaques. In this context, the practical application of, appropriate controls for, and interpretation of Duolink PLAs will be explicated.
  • Practice-Duolink in Biomedical Science, Session 1 Apr 28 2015 1:00 am UTC 75 mins
    J. Matthew Rhett, PhD Instructor, Department of Surgery, Medical University of South Carolina
    Gap junctions (GJs) are large aggregates of intercellular channels that facilitate the diffusion of small molecules and ions between two interacting cells. GJ intercellular channels are formed through the interaction of two half-channels, called hemichannels, composed of oligomerized connexin protein subunits. Both GJs and hemichannels have numerous important physiological and pathological roles in tissue functions including propagation of the action potential in the heart, tumor growth and metastasis, the inflammatory response and adaptive immunity, wound healing, and electrical synaptic transmission in the central nervous system. The most widely expressed connexin isoform is Cx43, and its regulation in the abovementioned processes has been a major focus of GJ research. Over the past two decades protein-protein interaction with the cytoplasmic carboxyl terminus of Cx43 has come to the fore as an endogenous mechanism for controlling the GJ life cycle, channel gating, and channel-independent functions. We have used the Duolink proximity ligation assay (PLA) as a technique to study protein interactions with Cx43 in cultured cells. Two unique aspects of the technology – specifically, subcellular localization and the binary nature of the labeling – in combination with standard immunofluorescent confocal imaging techniques have yielded unexpected insights into GJ ultrastructure, action potential conduction, and the mechanistic regulation of Cx43 trafficking and hemichannel accretion to GJ plaques. In this context, the practical application of, appropriate controls for, and interpretation of Duolink PLAs will be explicated.
  • Visualizing DNA Methylation (5mC) on a Specific Genomic Locus (SEPTIN9) 02 Apr 14 2015 3:00 pm UTC 75 mins
    Dr. Vikas Palhan, Sr. Scientist, Molecular Biotechnology, Sigma-Aldrich
    Although there are many techniques to study epigenetic marks such as DNA- and histone-methylation, on a genomic scale, there exists a need in the field to visualize these epigenetic marks at a single genomic locus in individual cells. Such an application requires a highly sensitive detection method. With this aim, a protocol was developed to perform in-situ hybridization followed by proximity ligation assay (a.k.a. Duolink®) and cell imaging to visualize DNA-methylation (5meC) on the SEPTIN9 promoter. SEPTIN9 promoter methylation is a known biomarker for colon cancer. After optimizing cross-linking, cell permeabilization and chromatin accessibility, the genomic specificity was ascertained by hybridizing with a pool of biotinylated-oligo probes that target the CpG islands in the human SEPTIN9 promoter. The Duolink assay was performed using anti-biotin and anti-5meC antibodies, corresponding proximity ligation assay probes, and Far Red detection reagents.
    Imaging by fluorescent microscopy revealed two red punctate spots in metastatic prostate cancer DU145 cells (diploid for chromosome 17 – location of SEPTIN9 gene) and three red spots in colon cancer SW480 cells (triploid for Chr17). No signal was observed in normal cells (BJ) or with non-specific oligo probes (LacZ). A decrease in Duolink signal was observed when the DU145 cells were treated with 5-AzaC, a drug known to block DNA-methylation. This proof of concept study will be extended to frozen and formalin fixed paraffin embedded human cancer tissue samples.
    Fluorescent imaging data will also be presented from a Duolink assay to monitor the interaction of EZH2 histone methyltransferase with the H3K27me3 epigenetic mark in prostate cancer (DU145) cells. Reduction in the Duolink signal demonstrated inhibition of EZH2 activity by the small molecule inhibitors SAHA and GSK343.
  • Visualizing DNA Methylation (5mC) on a Specific Genomic Locus (SEPTIN9) 01 Apr 14 2015 1:00 am UTC 75 mins
    Dr. Vikas Palhan, Sr. Scientist, Molecular Biotechnology, Sigma-Aldrich
    Although there are many techniques to study epigenetic marks such as DNA- and histone-methylation, on a genomic scale, there exists a need in the field to visualize these epigenetic marks at a single genomic locus in individual cells. Such an application requires a highly sensitive detection method. With this aim, a protocol was developed to perform in-situ hybridization followed by proximity ligation assay (a.k.a. Duolink®) and cell imaging to visualize DNA-methylation (5meC) on the SEPTIN9 promoter. SEPTIN9 promoter methylation is a known biomarker for colon cancer. After optimizing cross-linking, cell permeabilization and chromatin accessibility, the genomic specificity was ascertained by hybridizing with a pool of biotinylated-oligo probes that target the CpG islands in the human SEPTIN9 promoter. The Duolink assay was performed using anti-biotin and anti-5meC antibodies, corresponding proximity ligation assay probes, and Far Red detection reagents.
    Imaging by fluorescent microscopy revealed two red punctate spots in metastatic prostate cancer DU145 cells (diploid for chromosome 17 – location of SEPTIN9 gene) and three red spots in colon cancer SW480 cells (triploid for Chr17). No signal was observed in normal cells (BJ) or with non-specific oligo probes (LacZ). A decrease in Duolink signal was observed when the DU145 cells were treated with 5-AzaC, a drug known to block DNA-methylation. This proof of concept study will be extended to frozen and formalin fixed paraffin embedded human cancer tissue samples.
    Fluorescent imaging data will also be presented from a Duolink assay to monitor the interaction of EZH2 histone methyltransferase with the H3K27me3 epigenetic mark in prostate cancer (DU145) cells. Reduction in the Duolink signal demonstrated inhibition of EZH2 activity by the small molecule inhibitors SAHA and GSK343.
  • Late Stage Functionalization of Drug-Like Molecules Session 2 Mar 31 2015 3:00 pm UTC 60 mins
    Tim Cernak
    C-H functionalization is a powerful addition to the toolbox of the medicinal chemist. Modern C-H functionalization techniques hold the potential to enable the rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the preparation of biological probes. This presentation will describe a variety of high-value C-H functionalization chemistries, developed in house and in collaboration with academic groups, and give examples of how these technologies have been deployed successfully to impact drug discovery programs.
  • Late Stage Functionalization of Drug-Like Molecules Session 1 Recorded: Mar 31 2015 49 mins
    Tim Cernak
    C-H functionalization is a powerful addition to the toolbox of the medicinal chemist. Modern C-H functionalization techniques hold the potential to enable the rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the preparation of biological probes. This presentation will describe a variety of high-value C-H functionalization chemistries, developed in house and in collaboration with academic groups, and give examples of how these technologies have been deployed successfully to impact drug discovery programs.
  • Why We Use Cell Lines as Models: A 30 Year Journey and What Lies Ahead Recorded: Mar 26 2015 53 mins
    Jim Cooper, Cell Biology Application Scientist, Scientific Development Group, ECACC
    This webinar will discuss the evolving role of Cell Lines and Cell Culture and their usefulness as models of physiological function and disease. The webinar will review the depth, breadth and best use of currently available Cell Lines. The role played by Cell Lines in ensuring that the output of future research continues to be valid and credible will also be evaluated. This is the first of a three part webinar series focused on delivering a broad picture of the role of cell lines as models in scientific research, the various strategies and approaches available.
  • Molecular Annotation of EGFR Signaling-Associated Complexes in Human Cancer 02 Recorded: Mar 26 2015 53 mins
    Eric B. Haura M.D., Moffitt Cancer Center
    Mass spectrometry and other methods such as yeast two-hybrid can now accurately discern protein complexes or larger protein interactomes in diseases such as cancer, yet it is difficult to forward translate this knowledge into human samples. To overcome this hurdle, we began experiments using proximity ligation assays (PLA) to directly translate protein complexes into human tumor materials. Our assay reflects protein complexes between EGFR and GRB2 protein, a key adaptor protein necessary for EGFR pathway activation and coupling to downstream MAPK signaling. We annotated nearly 300 primary xenograft models (PDX) of cancer and show tumor subtype enrichment of EGFR:GRB2 signaling-associated complexes. Furthermore, tumors with abundant levels of EGFR:GRB2 signaling-associated complexes are more likely to respond to anti-EGFR antibody-based therapy. Finally, in 350 lung cancer tissues, across three distinct cohorts of patients, we demonstrate the ability of EGFR:GRB2 protein complexes to segregate tumors and show benefit to EGFR tyrosine kinase inhibitor therapy in patients whose tumors harbor high levels of EGFR:GRB2 signaling-associated complexes. This suggests that annotation of signaling-associated protein complexes in cancer tissues can not only molecularly annotate disease types but may also have predictive capacity for cancer therapeutics. This work opens up the human protein interactome as a new class of molecular markers for disease in a more practical manner. Proteins, encoded by DNA, do not work in isolation but instead function as part of multi-protein complexes that drive both normal and disease physiology. While we demonstrate the utility of this approach in cancer, receptor tyrosine kinase signaling and tyrosine kinase inhibitor therapeutics, our approach described here could have utility across a wide spectrum of both signaling-associated complexes and different types of disease, and thus would be attractive to a large audience.
  • Why We Use Cell Lines as Models: A 30 Year Journey and What Lies Ahead Recorded: Mar 26 2015 60 mins
    Jim Cooper, Cell Biology Application Scientist, Scientific Development Group, ECACC
    This webinar will discuss the evolving role of Cell Lines and Cell Culture and their usefulness as models of physiological function and disease. The webinar will review the depth, breadth and best use of currently available Cell Lines. The role played by Cell Lines in ensuring that the output of future research continues to be valid and credible will also be evaluated. This is the first of a three part webinar series focused on delivering a broad picture of the role of cell lines as models in scientific research, the various strategies and approaches available.
  • Molecular Annotation of EGFR Signaling-Associated Complexes in Human Cancer 01 Recorded: Mar 26 2015 50 mins
    Eric B. Haura M.D., Moffitt Cancer Center
    Mass spectrometry and other methods such as yeast two-hybrid can now accurately discern protein complexes or larger protein interactomes in diseases such as cancer, yet it is difficult to forward translate this knowledge into human samples. To overcome this hurdle, we began experiments using proximity ligation assays (PLA) to directly translate protein complexes into human tumor materials. Our assay reflects protein complexes between EGFR and GRB2 protein, a key adaptor protein necessary for EGFR pathway activation and coupling to downstream MAPK signaling. We annotated nearly 300 primary xenograft models (PDX) of cancer and show tumor subtype enrichment of EGFR:GRB2 signaling-associated complexes. Furthermore, tumors with abundant levels of EGFR:GRB2 signaling-associated complexes are more likely to respond to anti-EGFR antibody-based therapy. Finally, in 350 lung cancer tissues, across three distinct cohorts of patients, we demonstrate the ability of EGFR:GRB2 protein complexes to segregate tumors and show benefit to EGFR tyrosine kinase inhibitor therapy in patients whose tumors harbor high levels of EGFR:GRB2 signaling-associated complexes. This suggests that annotation of signaling-associated protein complexes in cancer tissues can not only molecularly annotate disease types but may also have predictive capacity for cancer therapeutics. This work opens up the human protein interactome as a new class of molecular markers for disease in a more practical manner. Proteins, encoded by DNA, do not work in isolation but instead function as part of multi-protein complexes that drive both normal and disease physiology. While we demonstrate the utility of this approach in cancer, receptor tyrosine kinase signaling and tyrosine kinase inhibitor therapeutics, our approach described here could have utility across a wide spectrum of both signaling-associated complexes and different types of disease, and thus would be attractive to a large audience.
  • Integrating the Proximity Ligation Assay (PLA) into your Research Program 02 Recorded: Mar 17 2015 49 mins
    Joe Roethele Director of Antibody Production, Bethyl Laboratories
    The proximity ligation assay (PLA) is a powerful technique for performing in situ analysis of antibody targets in cells or tissues. This antibody-based application is very robust, and will provide unique data on localization and/or interaction of proteins. The webinar will outline the development of PLA, using an approach that is designed to help all researchers—regardless of their level of experience with this application. Topics addressed will include the following: guidelines for getting started, tips on the crucial bioinformatics investigations involved with the planning phase, specific details on the bench-work associated with performing the assay, and troubleshooting suggestions to allow investigators to refine the assay and successfully integrate it into their research program.
  • Integrating the Proximity Ligation Assay (PLA) into your Research Program 01 Recorded: Mar 17 2015 51 mins
    Joe Roethele Director of Antibody Production, Bethyl Laboratories
    The proximity ligation assay (PLA) is a powerful technique for performing in situ analysis of antibody targets in cells or tissues. This antibody-based application is very robust, and will provide unique data on localization and/or interaction of proteins. The webinar will outline the development of PLA, using an approach that is designed to help all researchers—regardless of their level of experience with this application. Topics addressed will include the following: guidelines for getting started, tips on the crucial bioinformatics investigations involved with the planning phase, specific details on the bench-work associated with performing the assay, and troubleshooting suggestions to allow investigators to refine the assay and successfully integrate it into their research program.
  • Introduction to PLA and Duolink Session 2 Recorded: Mar 10 2015 46 mins
    Dr. Ola Söderberg, Uppsala University and Tom Juehne, Sigma-Aldrich
    Visualization of protein-protein interactions at endogenous levels of expression is a powerful advancement in Life Science. Duolink® is a versatile tool for detection, quantification and localization of cytoplasmic signaling events. PLA® provides the ability to see and quantitate protein posttranslational modifications, define complex interactions, illuminate complex protein clusters or amplify low abundant single events.
  • Introduction to PLA and Duolink Session 1 Recorded: Mar 10 2015 32 mins
    Dr. Ola Söderberg, Uppsala University and Tom Juehne, Sigma-Aldrich
    Visualization of protein-protein interactions at endogenous levels of expression is a powerful advancement in Life Science. Duolink® is a versatile tool for detection, quantification and localization of cytoplasmic signaling events. PLA® provides the ability to see and quantitate protein posttranslational modifications, define complex interactions, illuminate complex protein clusters or amplify low abundant single events.
  • Modifying Cell Lines for Target Discovery and Validation Recorded: Mar 3 2015 27 mins
    Ethan S. Patterson, PhD
    Recent advances in genome editing have opened new potential for a wide variety of specific genomic modifications in virtually any cell type. In this 30-minute seminar, we will discuss the process of genome editing, address factors affecting the design of a genome editing project, and explore the application of modified cell lines for target discovery and validation.
  • Purification & Workup of Organic Synthesis - Basics, Strategies & Methodology Recorded: Nov 6 2014 68 mins
    Jason Wrigley, Scientific Liaison Team - Analytical Chemistry (Sigma-Aldrich)
    Workup and purification can be a complicated and time consuming process. The webinar will offer some available options for streamlining this part of your workflow, and provide some guidance and strategic advice depending on budget, equipment and experience. Workup of aqueous fractions will also be discussed.

    With the need for results as quickly as possible we will discuss how to perform reaction monitoring as quickly as possible using standard HPLC systems. We will show, with an example, how you may be able to obtain your results in 1/3 of your current time if you are running isocratically, or with generic gradients, with 5um or 3um C18 HPLC columns.
  • 3D Cell Culture Innovations Session 2 Recorded: Nov 4 2014 58 mins
    Dr. Nicky Slawny Applications Director 3D Biomatrix Dr. John Dangerfield Chief Operating Officer Austrianova
    This 1 hour long webinar will cover innovations in 3D cell culture technologies. Technology experts will discuss the unique features of the Perfecta3D Hanging Drop Plates and Cell-in-a-Box live cell encapsulation system with special emphasis on research applications and techniques.

    Topics will include:
    •Overview of the Perfecta3D plates and Cell-in-a-Box system
    •3D culture system selection
    •Best practices
    •Research Applications
  • 3D Cell Culture Innovations Session 1 Recorded: Nov 4 2014 55 mins
    Dr. Nicky Slawny Applications Director 3D Biomatrix Dr. John Dangerfield Chief Operating Officer Austrianova
    This 1 hour long webinar will cover innovations in 3D cell culture technologies. Technology experts will discuss the unique features of the Perfecta3D Hanging Drop Plates and Cell-in-a-Box live cell encapsulation system with special emphasis on research applications and techniques.

    Topics will include:
    •Overview of the Perfecta3D plates and Cell-in-a-Box system
    •3D culture system selection
    •Best practices
    •Research Applications
Focusing on new / innovative technologies and industry challenges
The Sigma-Aldrich seminar series features scientific presentations from key specialists in analytical chemistry, chemistry and life sciences, on the practical and technical aspects of new developments and innovations, to help advance your research.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Retention Mechanisms in HILIC Chromatography: Robust Method Development
  • Live at: Jun 28 2012 6:00 pm
  • Presented by: David S. Bell, Ph.D.
  • From:
Your email has been sent.
or close
You must be logged in to email this